Skip to main content

Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development

Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a co-founder of Structure Therapeutics.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.